52
IRUS TotalDownloads
Altmetric
A bioengineered three-dimensional cell culture platform integrated with microfluidics to address antimicrobial resistance in tuberculosis
File | Description | Size | Format | |
---|---|---|---|---|
Bielecka mbio-2017-Bielecka-.pdf | Published version | 2 MB | Adobe PDF | View/Open |
Title: | A bioengineered three-dimensional cell culture platform integrated with microfluidics to address antimicrobial resistance in tuberculosis |
Authors: | Bielecka, MK Tezera, LB Zmijan, R Drobniewski, F Zhang, X Jayasinghe, S Elkington, P |
Item Type: | Journal Article |
Abstract: | Antimicrobial resistance presents one of the most significant threats to human health, with the emergence of totally drug-resistant organisms. We have combined bioengineering, genetically modified bacteria, longitudinal readouts, and fluidics to develop a transformative platform to address the drug development bottleneck, utilizing Mycobacterium tuberculosis as the model organism. We generated microspheres incorporating virulent reporter bacilli, primary human cells, and an extracellular matrix by using bioelectrospray methodology. Granulomas form within the three-dimensional matrix, and mycobacterial stress genes are upregulated. Pyrazinamide, a vital first-line antibiotic for treating human tuberculosis, kills M. tuberculosis in a three-dimensional culture but not in a standard two-dimensional culture or Middlebrook 7H9 broth, demonstrating that antibiotic sensitivity within microspheres reflects conditions in patients. We then performed pharmacokinetic modeling by combining the microsphere system with a microfluidic plate and demonstrated that we can model the effect of dynamic antibiotic concentrations on mycobacterial killing. The microsphere system is highly tractable, permitting variation of cell content, the extracellular matrix, sphere size, the infectious dose, and the surrounding medium with the potential to address a wide array of human infections and the threat of antimicrobial resistance. |
Issue Date: | 7-Feb-2017 |
Date of Acceptance: | 12-Jan-2017 |
URI: | http://hdl.handle.net/10044/1/45024 |
DOI: | https://dx.doi.org/10.1128/mBio.02073-16 |
ISSN: | 2150-7511 |
Publisher: | American Society for Microbiology |
Journal / Book Title: | MBIO |
Volume: | 8 |
Issue: | 1 |
Copyright Statement: | © 2017 Bielecka et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/). |
Sponsor/Funder: | Medical Research Council (MRC) |
Funder's Grant Number: | 515330101 |
Keywords: | Science & Technology Life Sciences & Biomedicine Microbiology MYCOBACTERIUM-TUBERCULOSIS ANTIBIOTIC-RESISTANCE EXTRACELLULAR-MATRIX IN-VITRO ANTITUBERCULOSIS DRUGS HOST PYRAZINAMIDE EXPRESSION EVOLUTION PATHOGEN 0605 Microbiology |
Publication Status: | Published |
Article Number: | ARTN e02073-16 |
Appears in Collections: | Department of Medicine (up to 2019) |